@dr_ijaay: You take a GLP-1, and two headlines land on your feed. The FDA warns about rare vision loss. A new study links stopping a GLP-1 to heart attacks, strokes, or death. So what are you supposed to do about your next dose? Here’s what I want you to take home 👇🏾 1️⃣ The eye condition is rare, but the symptoms are urgent. The FDA flagged a possible increase in nonarteritic anterior ischemic optic neuropathy (NAION). It happens when blood flow to the optic nerve, which carries signals from your eye to your brain, is reduced. Across the trials the FDA reviewed, the rates were about 6 cases per 100,000 people per year in the GLP-1 group and 4 per 100,000 per year in the comparison groups. That’s a difference of about 2 cases per 100,000 people per year. 2️⃣ The stopping study looked at people with type 2 diabetes. Among more than 80,000 adults with type 2 diabetes and no prior cardiovascular disease, those who stopped had more heart attacks, strokes, or deaths combined. Researchers looked back at health records, so the study found a link and couldn’t tell whether stopping itself caused the difference. So what do you do? If the headlines are making you rethink your next dose and you’re feeling well, keep taking your medication as prescribed and bring your questions to your prescriber. If you need to stop, ask what the plan is for managing your blood sugar and heart risk. If vision in one eye suddenly goes dark, gets blurry, or develops a blind spot, get emergency care right away, even if it doesn’t hurt. Save this so you know what to watch for. Follow for practical hospital tips and medical updates that affect you. For general education. Talk with your prescriber about your individual treatment plan. Studies: -FDA safety communication on GLP-1s and rare vision loss (NAION)⁠ -The Lancet Regional Health – Europe study on stopping GLP-1s in people with type 2 diabetes⁠ #g#glp1g#glp1sicknessn#naiond#diabetes

Cogniteve_MD 🇳🇬🇺🇸

Open In TikTok:

Region: US

Friday 13 November 2026 15:26:37 GMT